inclusion criteria: 1. 1. adult male or female individuals of ≥50 years old. 2. 2. in women of childbearing potential1, negative pregnancy test at inclusion/baseline. 3. 3. has confirmed sars-cov-2 infection as determined by pcr or validated antigen rapid diagnostic test2 from nasopharyngeal swabs ≤5 days prior to inclusion/baseline visit. 4. 4. symptomatic with mild or moderate covid-19 with symptoms onset date ≤ 7 days prior to inclusion/baseline visit. 1. a. mild covid-19: individuals who have any of the common signs and/or symptoms of covid-19 (i.e., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnoea, or abnormal chest imaging. 2. moderate covid-19: individuals who have evidence of lower respiratory disease by clinical assessment or imaging and a saturation of oxygen (spo2) ≥94% on room air at sea level. 5. 5. willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study. 6. 6. has understood the information provided and capable of giving informed consent. 1 a woman will be considered of childbearing potential if not permanently sterilized nor postmenopausal. permanent sterilization methods include tubal ligation, hysterectomy and bilateral oophorectomy. postmenopausal is defined as 12 months with no menses without an alternative medical cause. 2 panbiotm covid-19 ag rapid test (abbott), standardtm q covid-19 ag test (roche) or any other ce marketed test for sars-cov-2 ag detection.

inclusion criteria: 1. 1. adult male or female individuals of ≥50 years old. 2. 2. in women of childbearing potential1, negative pregnancy test at inclusion/baseline. 3. 3. has confirmed sars-cov-2 infection as determined by pcr or validated antigen rapid diagnostic test2 from nasopharyngeal swabs ≤5 days prior to inclusion/baseline visit. 4. 4. symptomatic with mild or moderate covid-19 with symptoms onset date ≤ 7 days prior to inclusion/baseline visit. 1. a. mild covid-19: individuals who have any of the common signs and/or symptoms of covid-19 (i.e., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnoea, or abnormal chest imaging. 2. moderate covid-19: individuals who have evidence of lower respiratory disease by clinical assessment or imaging and a saturation of oxygen (spo2) ≥94% on room air at sea level. 5. 5. willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study. 6. 6. has understood the information provided and capable of giving informed consent. 1 a woman will be considered of childbearing potential if not permanently sterilized nor postmenopausal. permanent sterilization methods include tubal ligation, hysterectomy and bilateral oophorectomy. postmenopausal is defined as 12 months with no menses without an alternative medical cause. 2 panbiotm covid-19 ag rapid test (abbott), standardtm q covid-19 ag test (roche) or any other ce marketed test for sars-cov-2 ag detection.

inclusion criteria: 1. adult male or female individuals of ≥50 years old. 2. in women of childbearing potential1, negative pregnancy test at inclusion/baseline. 3. has confirmed sars-cov-2 infection as determined by pcr or validated antigen rapid diagnostic test2 from nasopharyngeal swabs ≤5 days prior to inclusion/baseline visit. 4. symptomatic with mild or moderate covid-19 with symptoms onset date ≤ 7 days prior to inclusion/baseline visit. a. mild covid-19: individuals who have any of the common signs and/or symptoms of covid-19 (i.e., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnoea, or abnormal chest imaging. moderate covid-19: individuals who have evidence of lower respiratory disease by clinical assessment or imaging and a saturation of oxygen (spo2) ≥94% on room air at sea level. 5. willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study. 6. has understood the information provided and capable of giving informed consent. 1 a woman will be considered of childbearing potential if not permanently sterilized nor postmenopausal. permanent sterilization methods include tubal ligation, hysterectomy and bilateral oophorectomy. postmenopausal is defined as 12 months with no menses without an alternative medical cause. 2 panbiotm covid-19 ag rapid test (abbott), standardtm q covid-19 ag test (roche) or any other ce marketed test for sars-cov-2 ag detection.

inclusion criteria: 1. adult male or female individuals of ≥50 years old. 2. in women of childbearing potential1, negative pregnancy test at inclusion/baseline. 3. has confirmed sars-cov-2 infection as determined by pcr or validated antigen rapid diagnostic test2 from nasopharyngeal swabs ≤5 days prior to inclusion/baseline visit. 4. symptomatic with mild or moderate covid-19 with symptoms onset date ≤ 7 days prior to inclusion/baseline visit. a. mild covid-19: individuals who have any of the common signs and/or symptoms of covid-19 (i.e., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnoea, or abnormal chest imaging. moderate covid-19: individuals who have evidence of lower respiratory disease by clinical assessment or imaging and a saturation of oxygen (spo2) ≥94% on room air at sea level. 5. willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study. 6. has understood the information provided and capable of giving informed consent. 1 a woman will be considered of childbearing potential if not permanently sterilized nor postmenopausal. permanent sterilization methods include tubal ligation, hysterectomy and bilateral oophorectomy. postmenopausal is defined as 12 months with no menses without an alternative medical cause. 2 panbiotm covid-19 ag rapid test (abbott), standardtm q covid-19 ag test (roche) or any other ce marketed test for sars-cov-2 ag detection.

inclusion criteria: 1. 1. adult male or female individuals of ≥50 years old. 2. 2. in women of childbearing potential1, negative pregnancy test at inclusion/baseline. 3. 3. has confirmed sars-cov-2 infection as determined by pcr or validated antigen rapid diagnostic test2 from nasopharyngeal swabs ≤5 days prior to inclusion/baseline visit. 4. 4. symptomatic with mild or moderate covid-19 with symptoms onset date ≤ 7 days prior to inclusion/baseline visit. 1. a. mild covid-19: individuals who have any of the common signs and/or symptoms of covid-19 (i.e., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnoea, or abnormal chest imaging. 2. moderate covid-19: individuals who have evidence of lower respiratory disease by clinical assessment or imaging and a saturation of oxygen (spo2) ≥94% on room air at sea level. 5. 5. willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study. 6. 6. has understood the information provided and capable of giving informed consent. 1 a woman will be considered of childbearing potential if not permanently sterilized nor postmenopausal. permanent sterilization methods include tubal ligation, hysterectomy and bilateral oophorectomy. postmenopausal is defined as 12 months with no menses without an alternative medical cause. 2 panbiotm covid-19 ag rapid test (abbott), standardtm q covid-19 ag test (roche) or any other ce marketed test for sars-cov-2 ag detection.

inclusion criteria: 1. 1. adult male or female individuals of ≥50 years old. 2. 2. in women of childbearing potential1, negative pregnancy test at inclusion/baseline. 3. 3. has confirmed sars-cov-2 infection as determined by pcr or validated antigen rapid diagnostic test2 from nasopharyngeal swabs ≤5 days prior to inclusion/baseline visit. 4. 4. symptomatic with mild or moderate covid-19 with symptoms onset date ≤ 7 days prior to inclusion/baseline visit. 1. a. mild covid-19: individuals who have any of the common signs and/or symptoms of covid-19 (i.e., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnoea, or abnormal chest imaging. 2. moderate covid-19: individuals who have evidence of lower respiratory disease by clinical assessment or imaging and a saturation of oxygen (spo2) ≥94% on room air at sea level. 5. 5. willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study. 6. 6. has understood the information provided and capable of giving informed consent. 1 a woman will be considered of childbearing potential if not permanently sterilized nor postmenopausal. permanent sterilization methods include tubal ligation, hysterectomy and bilateral oophorectomy. postmenopausal is defined as 12 months with no menses without an alternative medical cause. 2 panbiotm covid-19 ag rapid test (abbott), standardtm q covid-19 ag test (roche) or any other ce marketed test for sars-cov-2 ag detection.